Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel

[1]  G. Small,et al.  Unmet needs in the diagnosis and treatment of Parkinson’s disease psychosis and dementia-related psychosis , 2022, International journal of psychiatry in clinical practice.

[2]  C. Ballard,et al.  Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. , 2021, Parkinsonism & related disorders.

[3]  C. Ballard,et al.  Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. , 2020, Parkinsonism & related disorders.

[4]  Carmen Rodriguez-Blazquez,et al.  The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study , 2020, Movement disorders : official journal of the Movement Disorder Society.

[5]  Danielle R. Fixen.  2019 AGS Beers Criteria for older adults , 2019, Pharmacy Today.

[6]  Daniel Weintraub,et al.  Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review , 2019, Movement disorders : official journal of the Movement Disorder Society.

[7]  K. Black.  Treatment of Parkinson's disease psychosis. , 2017, Medicina internacia revuo.

[8]  K. Chaudhuri,et al.  Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition , 2017, Parkinson's disease.

[9]  M. Cruz.  Pimavanserin (Nuplazid): A Treatment for Hallucinations and Delusions Associated With Parkinson's Disease. , 2017, P & T : a peer-reviewed journal for formulary management.

[10]  A. Damjanović,et al.  The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease , 2016, Behavioural neurology.

[11]  J. Filion,et al.  Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders , 2016, Journal of geriatric psychiatry and neurology.

[12]  O. Rascol,et al.  Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. , 2015, Journal of the American Medical Directors Association.

[13]  G. Halliday,et al.  Validation of the Psychosis and Hallucinations Questionnaire in Non‐demented Patients with Parkinson's Disease , 2015, Movement disorders clinical practice.

[14]  A. Hasan,et al.  Psychosis in Parkinson’s disease: identification, prevention and treatment , 2015, Journal of Neural Transmission.

[15]  J. Cummings,et al.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial , 2014, The Lancet.

[16]  J. Goldman,et al.  Treatment of Psychosis and Dementia in Parkinson’s Disease , 2014, Current Treatment Options in Neurology.

[17]  J. Cummings,et al.  Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. , 2013, Parkinsonism & related disorders.

[18]  K. Jellinger,et al.  Cerebral correlates of psychotic syndromes in neurodegenerative diseases , 2012, Journal of cellular and molecular medicine.

[19]  G. Stebbins,et al.  A 12-year population-based study of psychosis in Parkinson disease. , 2010, Archives of neurology.

[20]  G. Fénelon,et al.  Four novel mutations in the GCH1 gene of Chinese patients with dopa‐responsive dystonia , 2010, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[22]  Paolo Barone,et al.  The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[23]  K. Gwinn‐Hardy,et al.  Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group , 2007, Movement disorders : official journal of the Movement Disorder Society.

[24]  E. Montgomery.  Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. , 2007, Neurology.

[25]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[26]  W. Weiner,et al.  Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2006, Neurology.

[27]  W. Oertel,et al.  Development and evaluation of the Parkinson Psychosis Questionnaire , 2005, Journal of Neurology.

[28]  W. Oertel,et al.  Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. , 2005, Journal of neurology.

[29]  A. Destée,et al.  Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, The New England journal of medicine.